Claim OwnershipMedInsights Unleashed
Subscribed: 1Played: 2
Subscribe
Description
The MedInsights Unleashed Podcast aims to break down complex clinical data to provide insights from cutting-edge developments into tangible benefits for physicians, patients, and caregivers around the globe.
Zee Ramji and John Collins will engage with leading global healthcare specialists to bring the latest groundbreaking therapies to you.
To learn more about Zee and John, go deeper into each episode and access additional resources, go to https://medinsightsunleashed.com
Zee Ramji and John Collins will engage with leading global healthcare specialists to bring the latest groundbreaking therapies to you.
To learn more about Zee and John, go deeper into each episode and access additional resources, go to https://medinsightsunleashed.com
34 Episodes
Reverse
In this episode of MedInsights Unleashed, the discussion focuses on advanced chronic spine pain and when surgery becomes part of the care pathway. Dr. Rohan R. Lall, neurosurgeon at M Health Fairview University of Minnesota Medical Center, shares clinical perspective on evolving surgical approaches for patients with severe degeneration, instability, and chronic nerve-related pain. The conversation explores electrically enhanced transforaminal lumbar interbody fusion (e-TLIF), which combines spinal stabilization with targeted nerve stimulation, as well as broader trends in non-opioid pain management, minimally invasive surgery, robotics, and AI shaping modern spine care.
Dr. Lori Wirth, MD—Elizabeth and Michael Ruane Chair of Endocrine Oncology; Medical Director of the Massachusetts General Hospital Center for Head and Neck Cancers; and Professor of Medicine at Harvard Medical School—joins MedInsights Unleashed to discuss modern thyroid cancer care. She explores differentiated, medullary, and anaplastic disease; advances in diagnosis and treatment; the role of genomic testing, including BRAF V600E and RET; and the use of active surveillance for selected patients. Dr. Wirth underscores the importance of individualized care and shared decision-making, offering clear, practical insights for patients, caregivers, and clinicians navigating an evolving thyroid cancer landscape.
In this MedInsights Unleashed episode, we explore an emerging treatment for chronic degenerative disc disease called Hydrafil.Our guests are Bill Niland, CEO of ReGelTec Inc., and Dr. Anthony Lowman, PhD, Professor of Biomedical Engineering and Co-Founder/Chief Medical Officer at ReGelTec. They walk us through the science, creation, and development of this injectable hydrogel technology. Hydrafil is designed to help patients with lumbar back pain by restoring hydration and pressure inside the spinal disc, supporting its structure, and potentially reducing inflammation and pain.ReGelTec has launched its pivotal HYDRAFIL-D Study, a multicenter, randomized U.S. trial enrolling ~225 patients. For details, visit ClinicalTrials.gov and search: Degenerative Disc Disease + Hydrafil (NCT06011551 and NCT04984629).
In this episode of MedInsights Unleashed, Professor Pierre Gholam, MD., FAASLD, AGAF, returns to explore the transformative potential of GLP1-based therapies beyond diabetes and obesity. The discussion highlights how these drugs may play a groundbreaking role in **cancer prevention—particularly liver cancer—**by addressing the root causes of metabolic dysfunction, a growing public health crisis affecting millions of Americans. Prof. Gholam emphasizes the need for multidisciplinary collaboration among hepatologists, endocrinologists, and primary care providers to improve early detection and treatment of fatty liver disease through noninvasive diagnostics and proactive referral pathways. The episode also looks ahead to emerging oral and multi-agonist GLP1 therapies, marking a new frontier in personalized metabolic and oncologic care.
We’re honored to share a powerful new episode featuring Dr. Pierre Gholam, MD, FAASLD, AGAF—Professor of Medicine at Case Western Reserve University and Director of the Hepatobiliary Multidisciplinary Team at University Hospitals Seidman Cancer Center. With clarity and compassion, Dr. Gholam explores the complex and evolving nature of liver cancer, tracing its historical roots in viral hepatitis to today’s sharp rise in cases driven by fatty liver disease and alcohol use. He highlights both the breakthroughs and ongoing challenges in hepatocellular carcinoma (HCC) care—from early tyrosine kinase inhibitors to the promise of immune checkpoint inhibitors—while underscoring the critical need for improved screening strategies. Throughout the discussion, Dr. Gholam emphasizes the central role hepatologists play in managing HCC, from diagnosis to therapy.
We are privileged to have Dr. Ari Rosenberg, MD, and Dr. Maha Elsebaie, MD, MSc, from the University of Chicago, join us to discuss groundbreaking research in neoadjuvant head and neck cancer treatment. This episode explores how circulating HPV DNA, measured through a simple blood test, is emerging as a powerful tool to guide therapy decisions, personalize treatment, and potentially reduce the need for aggressive surgery or radiation.The discussion highlights early results from trials combining immunotherapy and chemotherapy before standard treatment, showing promising improvements in tumor response while reducing long-term side effects. This research is shaping the future of HPV-related head and neck cancer care and could change how clinicians plan treatments—bringing us closer to a more precise and less invasive approach.
Groundbreaking research presented at ASCO with Dr. Elinor Barsh, MD, and Dr. Jacob Keeling, MD, focuses on advances in immunotherapy for CTLA-4 resistant melanoma. This episode highlights the importance of recent progress, including the Phase I study of the antibody–drug conjugate ozuriftamab vedotin. Dr. Barsh and Dr. Keeling discuss new clinical trial data, evolving treatment pathways, and the significant reduction in mortality rates achieved with novel therapies. Their collaboration with the Sarah Cannon Research Institute underscores how innovative research can transform patient outcomes making melanoma more manageable despite its aggressive nature.
Dr. Sharlene Gill, MD, joins the MedInsights Unleashed podcast to discuss the Challenge Study's promising results on exercise in cancer care. Conducted over 17 years, the study revealed that colon cancer patients engaging in structured exercise post-treatment exhibited improved survival rates. The trial involved a comprehensive three-year program incorporating both in-person and virtual components, emphasizing physical activity alongside psychological support. Published in the New England Journal of Medicine (Structured Exercise after Adjuvant Chemotherapy for Colon Cancer) these findings could shift cancer treatment paradigms, advocating for the inclusion of formal exercise programs in post-chemotherapy care to enhance life expectancy and recovery in cancer patients.
In this episode of MedInsights Unleashed, Dr. Ari Goldman, MD, FAAOS, and Lewis Collins, OPA-C, ATC, OTC, from the Northwell Health Orthopedic Trauma and Surgery Team, uncover the facts on knee replacements. The discussion kicks off with a detailed look at knee anatomy and the factors leading to knee replacements, such as arthritis and genetic predispositions. The episode delves into the importance of maintaining knee health through exercise and weight management. They also explore how alignment issues elsewhere in the body can impact knee integrity and the outcomes of replacement surgery. The episode wraps up with insights into dietary considerations for bone quality and joint health.
Professor Philip A. Philip, MD, PhD, FRCP, Professor of Medical Oncology at Wayne State University School of Medicine and the Henry Ford Cancer Institute, returns to the MedInsights Unleashed podcast discusses the intricate topic of neuroendocrine tumors(NETs), including their rarity, the non-aggressive nature of many cases, and their potential functional characteristics. Prof. Phillip clarifies common misconceptions, advising listeners on the crucial role of accurate diagnosis and the use of grading systems to assess tumor aggressiveness. This episode not only benefits patients seeking understanding of their condition but also serves as a valuable resource for healthcare professionals dealing with these complex cancers.
In this episode of MedInsights Unleashed, Dr. Kriti Dhamija, MD, a second-year resident in the Department of Internal Medicine at Allegheny Health Network, Pittsburgh, Pennsylvania, USA, challenges the misconceptions around palliative care, particularly in pancreatic cancer. She explains why palliative care should begin at diagnosis, not at the end of life, and how early referral can reduce ER visits, hospital stays, and ICU admissions. Dr. Dhamija also explores the role of multidisciplinary teams, tackles persistent stigmas, and highlights how even resource-limited settings can improve care using team-based approaches and free guidelines. A must-listen for clinicians, patients, caregivers, and students alike.
In a recent episode of MedInsights Unleashed, Dr. Danny Rischin, MD, medical oncologist/clinician researcher at the Peter MacCallum Cancer Centre and Professor, Sir Peter MacCallum Department of Oncology, University of Melbourne, discusses the groundbreaking C-POST study focused on cutaneous squamous cell cancer. By utilizing the immunotherapy drug, cemiplimab, the study achieves a 68% reduction in the risk of recurrence, marking a significant step forward in adjuvant cancer therapy. Dr. Rischin explains the study's meticulous approach to identifying high-risk patients and its impressive 87% disease-free survival rate at two years. He also discusses the role of multidisciplinary care in effectively managing complex cancer cases, emphasizing the need for continued research in uncovering reliable biomarkers.
In this episode of MedInsights Unleashed, Professor Philip A. Philip, MD, PhD, FRCP, Professor of Medical Oncology at Wayne State University School of Medicine and the Henry Ford Cancer Institute, shares vital insights into one of the most challenging cancers to detect and treat—pancreatic cancer. He highlights the urgent need for early recognition of symptoms and the growing understanding of genetic risks, including BRCA mutations and family history.The discussion also covers emerging research into KRAS, common DNA mutation in tumors that is playing a major role in changing future targeted treatment strategies. With perspectives from both U.S. and global healthcare systems, this episode emphasizes the power of awareness, timely action, and the promise of personalized medicine in improving outcomes for patients.
In this hard-hitting episode of MedInsights Unleashed, we tackle the escalating crisis of drug-related medical emergencies with guest speaker Eric Prach, MAS, BPsych—an EMT and police officer on the frontlines. This episode uncovers the harsh realities of fentanyl-laced overdoses, the rise of synthetic additives like Xylazine, and the increasing concern over Kratom use among young individuals.Eric provides critical insights into the life-saving role of Narcan, the challenges EMS teams face in overdose response, and the alarming prevalence of drug use in schools. As volunteer EMT numbers decline, hybrid staffing models are becoming the new norm. This conversation serves as a wake-up call, underscoring the urgent need for awareness, prevention, and preparedness in combating the street drug epidemic.4o
Episode Summary:This is the second episode in our series on colorectal cancer. In this episode of MedInsights Unleashed, we sit down with Prof. Paulo Hoff, MD, PhD, from the University of São Paulo, Brazil, to discuss the latest developments in colorectal cancer treatment. With cases increasing, especially among younger adults, the conversation underscores the importance of early screening and detection. Prof. Hoff explains how tumor location—right vs. left side—affects treatment strategies, the role of genetic markers in guiding decisions, and how immunotherapy is shaping new treatment options. Listeners will gain a clearer understanding of molecular profiling, personalized care, and what these advancements mean for patients facing colorectal cancer.
Osteoporosis is often viewed as a women’s disease, but in this episode of MedInsights Unleashed, Dr. Tom Forfa, MBBS, reveals why men are also at serious risk. A retired physician and osteoporosis educator from Queensland, Australia, Dr. Forfa shares his personal journey, from multiple fractures to a delayed diagnosis, highlighting the need for early screening and awareness.This episode uncovers misconceptions, risk factors, and treatment options, including an unexpected dietary ally—prunes. Recent research suggests that daily prune consumption may help maintain bone density and support fracture healing, making it a promising nonpharmacologic approach to osteoporosis prevention.👉 If you think osteoporosis only affects women, think again.
In this latest episode of MedInsights Unleashed, we are delighted to welcome Dr. Paulo Hoff, MD, PhD, Professor of Clinical Oncology at the Department of Radiology and Oncology, University of São Paulo. Dr. Hoff discusses the rising incidence of colorectal cancer in younger populations, highlighting key risk factors including poor diet, sedentary lifestyle, and obesity. He emphasizes the critical importance of beginning regular screening at age 45.The discussion covers the complete treatment journey, from initial diagnosis through staging—which determines both local and distant tumor spread—to help create optimal treatment plans. Dr. Hoff explains that some patients may require temporary or permanent colostomy procedures.A significant focus is placed on the emerging total neoadjuvant treatment (TNT) approach, which administers all chemotherapy and radiation before surgery to improve outcomes. The episode concludes by emphasizing the value of collaborative care, bringing together different oncology specialists for comprehensive treatment
In this MedInsights Unleashed episode, Dr. Christine Simmons, MD, Associate Professor in the Faculty of Medicine at UBC (University of British Columbia) and specialist in breast cancer and sarcoma, provides an in-depth exploration of the breast cancer journey, focusing on diagnosis, staging, and cutting-edge treatments for triple-negative breast cancer. She discusses the critical role of subtype differentiation and personalized care, with a particular emphasis on advancements in managing triple-negative breast cancer. Highlighting the transformative potential of immunotherapy, Dr. Simmons likens it to removing the "invisibility cloak" from cancer cells, enabling the immune system to target them effectively. Balancing innovation with caution, she also addresses the possible side effects of these treatments, offering a nuanced perspective on this rapidly evolving field. This episode is an essential resource for understanding the challenges and breakthroughs in breast cancer care.
In this MedInsights Unleashed episode, Dr Christine Simmons MD, Associate Professor in the Faculty of Medicine at UBC (University of British Columbia) and specialist in breast cancer and sarcoma, discusses breast cancer awareness, emphasizing the importance of regular screenings for early detection—especially post-COVID-19, as screening rates have significantly dropped. Early detection leads to better outcomes and less aggressive treatments. Dr. Simmons highlights that breast cancer is not exclusively a women’s issue, as men can develop it too. Additionally, she underscores the role of genetics, such as BRCA mutations, in increasing breast cancer risk. Preventative strategies like regular exercise, limiting alcohol intake, and a healthy diet are important in preventing breast cancer. She discusses the role of low-dose tamoxifen for high-risk patients, and for those with significant risk, preventive mastectomy can reduce cancer likelihood. Diagnostic imaging like mammograms and ultrasounds are essential to distinguish benign from malignant growths, often followed by a biopsy. Dr. Simmons’s insights encourage proactive health measures and vigilance in cancer prevention.
Elen Baloyan, MD, Oncology Fellow at Yeolyan Hematology and Oncology Center in Yerevan, Armenia, shares her insightful journey in this MedInsights Unleashed podcast episode. She addresses the financial toxicity affecting both doctors and patients in Armenia, which often leads to treatment refusals and late diagnoses due to high costs. Despite government efforts to support cancer care, the financial burden remains significant. Elen discusses the future of clinical trial development and the hope it brings to patients through the Immune Oncology Research Institute in Armenia. Elen's diverse roles, from medical practice to managing editor at OncoDaily, highlight pressing issues and her commitment to finding solutions. This episode emphasizes the need for greater financial support and education in the medical field.
Comments
Download from Google Play
Download from App Store
United States